TNF and psoriasis: In clinical trial SPIRIT-P2, IXE improved the signs and symptoms of patients with active PsA (inadequate responders to tumor necrosis factor [TNF] inhibitor) along with a safety profile consistent with previous studies involving both PsA and psoriasis [5, 6].